Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)
A phase II clinical trial evaluating the efficacy and tolerability of induction and consolidation chemotherapy comprising Fludarabine, cytarabine and attenuated-dose Idarubicin (modified-FLAI) in the elderly patients with acute myeloid leukemia.
Acute Myeloid Leukemia
DRUG: induction chemotherapy (fludarabine, cytarabine, idarubicin)
Complete remission rate, Rate of complete remssion (CR) after two cycles of m-FLAI induction
Rate of serious adverse events (SAE), Number of patients dying from SAE related to m-FLAI induction|Event Free Survival, Event free survival defined as a period from study enrollment to death by from cause or relapse of disease after complete remission|overall survival, Overall survival defined as a period from study enrollment to death from any cause|Predictive factors for Complete remission, Compare complete remission rate according to existence of specific chromosome abnormality and Charlson comorbidity index to evaluate predicative impact of these factors.
A phase II clinical trial evaluating the efficacy and tolerability of induction and consolidation chemotherapy comprising Fludarabine, cytarabine and attenuated-dose Idarubicin (modified-FLAI) in the elderly patients with acute myeloid leukemia.